Active immunizations against diphtheria, tetanus andpolio in children after the age of 6, adolescents and adults as a booster dose after primary vaccination. The vaccine is not indicated in the primary vaccination. Use according to official recommendations for vaccination schedules.
Composition:
1 dose (0.5 ml) contains not less than 2 IU diphtheria toxoid, not less than 20 IU tetanus toxoid and inactivated poliovirus (40 U. polio virus type 1 antigen - Mahoney strain, 8 j. polio virus type 2 antigen - strain MEF-1, 32 j. polio virus antigen D type 3 - strain Saukett).
Action:
Diphtheria, tetanus and vaccinepolio (inactivated), adsorbed on hydrated aluminum hydroxide, with a reduced content of antigens. Concentration of diphtheria toxoid is reduced to 1/6 of the dose used in primary vaccination. Protective level of antibodies against diphtheria, tetanus andpolio is achieved one month after the vaccine was given as a booster dose. The vaccine resistance lasts at least 10 years.
Contraindications:
Hypersensitivity to any of the components of the vaccine, neomycin, streptomycin or polymyxin B. The occurrence of an increased hypersensitivity or neurological disorder after prior administration of a diphtheria-containing or tetanus toxoid vaccine combined with or without an inactivated vaccine againstpolio. Fever and acute infection (vaccinations should be postponed). Do not administer intravascularly, intradermally, subcutaneously.
Precautions:
In patients with immune disorders or undergoing immunosuppressive therapy, it is recommended that the vaccination be postponed until recovery or termination of treatment. However, it is recommended to vaccinate people with chronic immunodeficiency disorders (eg HIV-infected), although the immune response may be impaired in these patients. Vaccinations should be avoided for people who have completed the primary immunization program in the last 5 years or have received a booster dose of diphtheria or tetanus vaccine. If after the previous administration of a tetanus toxoid vaccine, Guillain-Barré syndrome or shoulder nerve inflammation occurred, the decision to administer any tetanus toxoid vaccine should be made after considering the potential benefits and possible risks associated with vaccination. As with all injectable vaccines, this vaccine must be administered with caution to people with thrombocytopenia or a coagulation disorder, as these patients may experience bleeding after intramuscular administration. At the time of vaccination, supervision and appropriate assistance should be provided in case of an anaphylactic reaction following administration of the vaccine.
Pregnancy and lactation:
Although there are no reports of teratogenic effects, the vaccine is not recommended for pregnant women. Pregnant women at risk of tetanus infection after wounds are better off with an adsorbed tetanus vaccine. Breastfeeding is not a contraindication to vaccination.
Side effects:
Very common: reactions at the injection site (pain, erythema, induration, swelling, lump). Common: headache, dizziness, nausea, vomiting, fever. Uncommon: enlarged lymph nodes, unwellness, muscle pain. Rarely: joint pain. In addition, hypotension, convulsions, Guillain-Barré syndrome, shoulder plexus neuropathy, transient paraesthesia and hypoaesthesia in the vaccine limb, vasovagal syncope, abdominal pain, diarrhea, allergy-like reactions such as various types of rashes, pruritus, urticaria, facial edema (suggesting a possible hypersensitivity reaction), pain in the limb that the vaccine was given to, large reactions at the application site (> 50 mm), including extensive swelling of the limb, which can range from the injection site to one of the neighboring joints, aseptic abscess, pallor , weakness that occurs and usually disappears within a few days, chills, flu-like symptoms, usually on the day of vaccination, immediate hypersensitivity reactions: urticaria,Quincke edema and anaphylactic shock.
Dosage:
Intramuscularly (preferably in the deltoid muscle). A booster dose (0.5 ml) is given according to official vaccination guidelines. For adults vaccinated more than 10 years ago or those who do not know if they have been vaccinated, a second dose of the vaccine may be considered after a month, especially if there is a risk of diphtheria.
(C)
